緑内障治療薬の世界市場（2023年）：2022年～2028年の分析

当レポートでは、世界の緑内障治療薬市場について調査し、緑内障治療薬市場の現状を分析し、今後5年間の市場パフォーマンスを予測しています。また、パイプライン動向、および市場に参入する企業の企業プロファイルなどを提供しています。

SAMPLE VIEW

目次

• 緑内障の種類とリスクファクター
• 緑内障の診断と治療
• 眼科医や検眼医を含む緑内障ケア提供者の世界的見解
• 世界における緑内障の有病率に関する現況と5ヶ年予測
• 市場における緑内障治療薬とその作用機序
• ジェネリック薬とブランド薬との比較と市場への影響
• 緑内障医薬品の開発パイプライン
• 緑内障治療薬を製造・販売している企業のプロファイル

The "2023 Glaucoma Pharmaceuticals Market Report" features new regional sales forecasts, market share analysis of generics and branded drugs by drug class in the United States, new analysis of pipeline products, and a summary of ongoing clinical trials. Also included is an updated analysis of the global and regional prevalence of glaucoma and the latest breakdown of diagnosis and treatment paradigms.

SAMPLE VIEW

The report also features new survey data from the United States and Europe, including ophthalmologists' preferences for sustained drug delivery.

This report provides analysis of current markets for glaucoma medications and forecasts market performance over the next five years. The global market is analyzed based on Market Scope's eight regional/economic categories (the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World), and also uses these categories in global forecasts for disease prevalence. In addition, the report explores data and information on the disease process, glaucoma populations, glaucoma care, and a range of additional topics intended to provide depth and context to the reader's understanding of this ophthalmic segment.

Coverage includes:

• Types of glaucoma and risk factors.

• Diagnosis and treatment of the disease.

• A global view of glaucoma care providers, including ophthalmologists and optometrists.

• Current estimates and five-year forecasts for disease prevalence worldwide.

• Glaucoma medications in the marketplace and their mechanisms of action.

• Discussion of generic versus branded drugs and their market impact.

• The development pipeline for glaucoma pharmaceuticals.

• Profiles of companies making and marketing glaucoma medications.

Author Profile:

Peter Downs

Peter Downs has more than 30 years of experience as a business and medical journalist and investigative reporter. He has written for a variety of medical industry publications, including the Medical Business Journal, CBS HealthWatch, and Oncology News International.

Prior to joining Market Scope in 2015 and turning his attention to ophthalmology, Peter analyzed markets for organ and tissue transplantation. Since joining Market Scope, he has traveled to several markets outside the US, including China, Europe, and India, to study ophthalmology at the local level.

In addition to his research and writing efforts on the ophthalmic market, he is also a contributor to Ophthalmic Market Perspectives, the firm's monthly industry newsletter.